🔎 Trials Near Me

Home › Endometrial Cancer › Georgia

Endometrial Cancer clinical trials in Georgia

25 studies for Endometrial Cancer are looking for participants at sites in Georgia.

Cities in Georgia

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Emory Winship Cancer Institute, Atlanta
  • Augusta University, Augusta
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 28, 2026 · NCT06586957

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Piedmont Hospital, Atlanta
  • and 4 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05256225

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • Augusta University Medical Center, Augusta
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • and 2 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT07198074

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Piedmont Hospital, Atlanta
  • and 3 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Emory University School of Medicine - Winship Cancer Institute, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Georgia Cancer Center at Augusta University, Augusta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  • Emory Winship Cancer Inst., Atlanta
  • Emory Winship Cancer Inst., Atlanta
  • Northside Hospital Atlanta, Atlanta
  • and 1 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Augusta University Georgia Cancer Center, Augusta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT06270706

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Piedmont Healthcare, Atlanta
RecruitingObservational study
Ages 18 and older · Women · Updated Apr 17, 2026 · NCT05051722

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • North Georgia Health System, Gainesville
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

  • Augusta University, Augusta
RecruitingPhase 2
Ages 18 to 70 · Women · Updated Oct 30, 2025 · NCT06481592

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Atlanta
  • Massive Bio SYNERGY-AI site, Savannah
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

A Beta-only IL-2 ImmunoTherapY Study

  • Emory - Winship Cancer Institute, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2025 · NCT05086692

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  • Northside Hospital, Atlanta
  • St. Joseph, Savannah
RecruitingPhase 2/3
Ages 18 and older · Women · Updated May 2, 2024 · NCT05797831

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.